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ABSTRACT
Objectives: Infectious diseases consultation (IDC) in
adults with Staphylococcus aureus bacteraemia (SAB)
has been shown to improve management and
outcome. The aim of this study was to evaluate the
impact of IDC on the management of SAB in children.
Study design: Observational cohort study of children
with SAB.
Setting: Cambridge University Hospitals National
Health Service (NHS) Foundation Trust, a large acute
NHS Trust in the UK.
Participants: All children with SAB admitted to the
Cambridge University Hospitals NHS Foundation Trust
between 16 July 2006 and 31 December 2012.
Methods: Children with SAB between 2006 and 31
October 2009 were managed by routine clinical care
(pre-IDC group) and data were collected retrospectively
by case notes review. An IDC service for SAB was
introduced in November 2009. All children with SAB
were reviewed regularly and data were collected
prospectively (IDC group) until 31 December 2012.
Baseline characteristics, quality metrics and outcome
were compared between the pre-IDC group and IDC
group.
Results: There were 66 episodes of SAB in 63
children—28 patients (30 episodes) in the pre-IDC
group, and 35 patients (36 episodes) in the IDC group.
The median age was 3.4 years (IQR 0.2–10.7 years).
Patients in the IDC group were more likely to have
echocardiography performed, a removable focus of
infection identified and to receive a longer course of
intravenous antimicrobial therapy. There were no
differences in total duration of antibiotic therapy,
duration of hospital admission or outcome at 30 or
90 days following onset of SAB.
Conclusions: IDC resulted in improvements in the
investigation and management of SAB in children.
INTRODUCTION
Staphylococcus aureus bacteraemia (SAB) is a
serious infection that leads to significant mor-
bidity and mortality in adults and children.1 2
S. aureus causes significant disease in the
paediatric population, occurring in 1.5% of
all neonatal intensive care unit (ICU) admis-
sions,3 and 6/100 000 children older than
1 year of age.4 In neonates, SAB is almost
always hospital acquired, and is frequently
due to intravascular catheter (IVC)-associated
infections.3–6 The majority of non-neonatal
cases of SAB are community-acquired; those
that are hospital-acquired infections are
usually IVC associated.7 8
Identified risk factors for the development
of SAB in the paediatric population include
having a pre-existing medical condition, pro-
longed hospitalisation, the presence of an
IVC and HIV infection.1 3–6 9 10 Mortality
from SAB in the adult population is about
30%.11 Mortality rates in the paediatric popu-
lation tend to be lower, but can be up to
15% in neonates and/or children with
comorbidities.1 5 9 12 13 Given that SAB
causes a substantial burden of disease in the
paediatric population, strategies to improve
Strengths and limitations of this study
▪ This is the first study to examine the impact of
introduction of infectious diseases consultation
(IDC) on the management of Staphylococcus
aureus bacteraemia (SAB) in children.
▪ We found that IDC was associated with an
improvement in investigation and management
of SAB, but there was no difference in mortality
between the pre-IDC and IDC groups.
▪ The main limitation of the study was the size of
the study population, which may explain the lack
of mortality benefit.
▪ The study was conducted in a tertiary referral
centre, where clinical management is likely to
have been good prior to introduction of the IDC,
and may not be generalisable to other settings.
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management, prevent the complications of SAB and
reduce mortality are a clinical priority.
The impact of infectious disease consultation (IDC) in
adults with SAB has been extensively studied.14–23
IDC has been associated with improved adherence to
guidelines, including appropriate and targeted investiga-
tion, optimal duration of antibiotic therapy and a
reduction in complicated infection, morbidity and mor-
tality.14 16–18 22 24–27 In contrast, the impact of an IDC on
the management and outcomes of SAB in children has
not previously been evaluated. The aim of this study was
to determine the effects of routine IDC on the investiga-
tion, management and outcome of children with SAB.
MATERIALS AND METHODS
Study setting and participants
Cambridge University Hospitals National Health Service
Foundation Trust (CUH) is a tertiary referral centre for
paediatrics in the east of England. The paediatric
service has a 22-bed medical and surgical ward, a 17-bed
paediatric haematology and oncology ward, an 11-bed
paediatric ICU and high dependency unit (caring for
children aged from 0 to 16 years) and a 12-bed surgical
and medical ward for children aged up to 3 years. The
Rosie Hospital, the on-site mother and baby hospital,
has a 17-cot neonatal ICU and a 10-cot Special Care
Baby Unit.
Study design
We conducted an observational cohort study of all chil-
dren with SAB admitted to CUH between 16 July 2006
and 31 December 2012. In November 2009, an IDC
service for all patients with SAB was established at CUH.
Data were collected from 2006 to 2009 by a retrospective
review of the medical records, and prospectively there-
after during the IDC service. Patients with blood cul-
tures that were considered to be contaminants (afebrile
with no clinical evidence of infection) or with polymi-
crobial blood cultures were excluded from the analysis.
Microbiological investigation
Blood cultures were collected and incubated at 37°C for
5 days using the BacT/Alert 3D system (bioMérieux,
Basingstoke, UK). Blood cultures that flagged positive
were examined by microscopy and presumptively identi-
fied as S. aureus using a thermostable nuclease test.28
Colonies of S. aureus were identified by routine methods
after a further overnight incubation. Identification of S.
aureus was performed using a commercial latex agglutin-
ation test (Staphaurex, Oxoid Ltd, Basingstoke, UK)
until 2011 and then using matrix-assisted laser desorp-
tion ionisation time-of-flight mass spectroscopy (Bruker
Daltonik, Bremen, Germany). Antibiotic susceptibilities
were determined using disc diffusion testing, according
to the British Society for Antimicrobial Chemotherapy
standards.29 Throughout the study period a clinical
microbiologist provided telephone advice to the clinical
team for all patients with SAB, and attended weekly
ward rounds on the paediatric oncology ward and paedi-
atric ICU.
Study procedures
Prior to November 2009, all patients with S. aureus bac-
teraemia were managed by their primary clinical care
team, with telephone advice from the microbiologists.
From November 2009, all patients with SAB were
reviewed by an infectious disease Specialist Registrar or
Consultant, following presumptive identification of
S. aureus in blood cultures. The assessment included
clinical history to determine symptoms of infection, and
physical examination to determine possible foci of infec-
tion. Patients underwent clinical review daily by their
primary care team and at least weekly by the IDC team
during their inpatient stay. Demographic, clinical and
microbiology data were collected using a standard case
record form, and entered into an electronic database.
An IVC was considered to be the focus of infection if
there was evidence of inflammation at the catheter exit
site and/or a vascular catheter tip culture positive for
S. aureus, without clinical evidence of another source of
bacteraemia.30 Thrombophlebitis was diagnosed when
there was clinical evidence of infection and inflamma-
tion along a blood vessel or when ultrasound or other
imaging confirmed the presence of intravascular throm-
bosis in the setting of suspected infection. Bone and
joint infections were defined according to the USA
Centers for Disease Control and Prevention criteria.31
The lung was considered to be the source of infection
when there was clinical, radiological and/or microbio-
logical evidence of pulmonary infection. Soft tissue
infection was considered to be the source of the bacter-
aemia if the clinical signs of a known or suspected soft
tissue infection predated or were present at the time of
bacteraemia.14 A deep tissue abscess was defined by
radiological imaging criteria. Infective endocarditis (IE)
was diagnosed according to the modified Duke
criteria.32 33
A SAB episode was defined as being greater than or
equal to 14 days from a previous episode, in the absence
of persistent bacteraemia or focus of infection. A sec-
ondary site of infection was defined as a site of infection
separate from the primary site of infection that was not
present at the time of the initial examination.
Healthcare-associated bloodstream infection was defined
according to previously published criteria.34 Hospital-
acquired infection was defined according to the USA
Centers for Disease Control and Prevention.31
Community-acquired infections were defined as those
patients with a positive blood culture taken at or within
48 h of admission who did not meet criteria for
healthcare-associated bloodstream infection.34 Patients
were classified as having uncomplicated SAB if blood
cultures were negative 2–4 days after the initial blood
culture was positive, if they had defervesced at 72 h, if
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there was no evidence of metastatic disease or endocar-
ditis or if they had a catheter-related infection.35
Appropriate antimicrobial therapy was defined as
therapy to which the isolate was determined to be sus-
ceptible by antimicrobial disc susceptibility testing. The
duration of therapy was the length of time that a patient
received antibiotics to which the isolate was susceptible.
An underlying medical condition was defined as any
chronic medical condition that was present at the time
of bacteraemia. Serum C reactive protein, blood white
cell counts and platelet counts were measured on the
day of, or within 48 h postbacteraemia. Duration of hos-
pital admission and outcome at 30 and 90 days postbac-
teraemia was recorded for all patients.
Treatment recommendations
Antimicrobial treatment recommendations were pro-
vided for all children with SAB, based on existing evi-
dence on the management of SAB in adults.14 36–39
These included removal of a removable focus of infec-
tion,14 performing repeat blood cultures at 48–96 h,36
performing a transthoracic echocardiogram, performing
radiological imaging of suspected deep foci of infection,
treating uncomplicated infection with 14 days of intra-
venous antibiotics,37 treating complicated infections with
a minimum of 28 days of intravenous antibiotics,38 and
using β-lactam therapy as the mainstay of treatment for
methicillin-susceptible S. aureus.39
STATISTICAL ANALYSIS
Data were analysed using STATAV.12 (StataCorp, College
Station, Texas, USA). Categorical variables were analysed
using Fisher’s exact test and reported as the number
and per cent. Continuous variables were compared
using the Mann Whitney U test and reported as the
median and IQR. Mortality was analysed per patient (ie,
only the first bacteraemia episode was analysed).
ETHICS STATEMENT
Written informed consent from participants was not
required as the study was conducted as a service
evaluation.
RESULTS
Patient characteristics
Between July 2006 and December 2012, 71 children had
one or more blood cultures that were positive for S. aureus.
Sixty-three children (66 episodes) were included in the
study. Five children (six episodes) were excluded because
of polymicrobial bacteraemia and three patients (three
episodes) were excluded because the cultures were consid-
ered to be contaminants. Thus, 28 patients (30 episodes)
were included in the pre-IDC group, and 35 patients (36
episodes) in the IDC group. The study schema is sum-
marised in figure 1. Four of 30 episodes (13.3%) received
an IDC before the service was implemented in 2009, and
34 of 36 episodes (94.4%) received an IDC after the
service was implemented in 2009.
The baseline characteristics of the two groups were
similar (table 1). The clinical features for SAB were like-
wise similar, apart from an increased proportion of
IVC-related infections in the IDC group (61.3% vs
26.7%, p<0.01; table 2). A higher proportion of patients
had an unidentified focus of infection in the pre-IDC
group compared with the IDC group (23.3% vs 5.6%,
p=0.07). Risk factors for SAB were also similar apart
from an increased frequency of prosthetic material in
the IDC group (72.2% vs 46.7%, p=0.04; table 3).
Clinical management
A service evaluation of the IDC service was conducted,
the results of which are summarised in table 4. In the
IDC group, 34/36 episodes had an infectious diseases
review, with a median time to review of 2 days (range 1–
4 days). Patients in the IDC group were more likely to
have transthoracic echocardiography performed (80.6%
vs 33.3%, p<0.01). They were also more likely to have a
removable focus of infection identified (43.9% vs 23.3%,
p<0.01), although there was no difference between the
two groups in the likelihood of removal, or the time to
removal. In the IDC group, two patients did not have
their IVC removed, despite the recommendation to do
so, because of concerns about difficulty in
re-establishing vascular access. There was no difference
in the number of repeat blood cultures performed
between groups.
Antimicrobial therapy
There was no difference between the two groups in the
time taken to initiate appropriate antimicrobial therapy.
Patients in the IDC group were more likely to receive a
longer duration of intravenous antimicrobial therapy (18
vs 13.5 days, p=0.04), although there was no difference
in total duration of therapy (intravenous and oral)
between the two groups. In patients with complicated
SAB, the duration of intravenous antibiotic therapy was
longer in the IDC group (22 vs 14 days, p=0.02),
although there was no difference in total duration of
antibiotic therapy (intravenous and oral) between the
two groups. Patients in the IDC group were more likely
to receive a longer duration of intravenous therapy if
their repeat blood culture result was positive (p<0.01).
In patients with uncomplicated SAB. there was no differ-
ence between groups in the duration of intravenous anti-
biotics, or the total duration of antibiotic therapy. In
terms of compliance with recommended standards for
duration of therapy, patients in the IDC group were
more likely to meet these standards compared with
patients in the non-IDC group, both for complicated
SAB (42.1% vs 13.3%, p=0.13) and uncomplicated SAB
(68.4% vs 46.7%, p=0.14). There was no difference in
the proportion of patients receiving β-lactam therapy for
methicillin-sensitive S. aureus bacteraemia between the
two groups.
Saunderson RB, Gouliouris T, Cartwright EJ, et al. BMJ Open 2014;4:e004659. doi:10.1136/bmjopen-2013-004659 3
Open Access
copyright.
 o
n
 M
arch 6, 2020 at Cam
bridge University Library. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2013-004659 on 1 July 2014. Downloaded from 
Outcome of SAB
The duration of hospital admission was similar in the
pre-IDC and IDC groups, and in those with uncompli-
cated and complicated SAB (table 4). SAB was recorded
in the discharge summary in the majority of patients in
both groups. Four secondary infections were diagnosed,
three in the IDC group and one in the pre-IDC group.
In the IDC group, the secondary infections were tricus-
pid valve endocarditis (in a very low birthweight neonate
with patent ductus arteriosus), pneumonia and osteo-
myelitis, respectively. One child in the non-IDC group
developed osteomyelitis. There were three cases of recur-
rent bacteraemia within 90 days—two in the pre-IDC
group and one in the IDC group. Three children died
within 30 days of SAB, all in the IDC group, giving an
overall 30-day mortality rate of 4.8%. One death
occurred in a child with metastatic cancer that was not
attributed to SAB. The other two deaths were deemed
attributable to SAB, as blood cultures were positive at
the time of death. One patient was a neonate and died
prior to IDC, and the second case had cerebellar
atrophy, developmental delay and was receiving total par-
enteral nutrition. The 90-day mortality rate was 7.9%.
Two patients died between 30 and 90 days post-SAB,
both in the pre-IDC group. One patient had metastatic
cancer, and the other had complex congenital heart
disease.
DISCUSSION
To the best of our knowledge, this is the first study to sys-
tematically examine the impact of introduction of an
IDC service on the management of SAB in children. We
compared the clinical features, management and out-
comes of all children presenting with SAB to our hos-
pital between July 2006 and December 2012, before and
after introduction of an IDC service. The main findings
of the study were that patients in the IDC group were
more likely to have echocardiography performed, a
removable focus of infection identified and to receive a
longer course of intravenous antibiotic therapy. These
findings concur with those from previous studies of IDC
Figure 1 Study schema of
paediatric patients with
Staphylococcus aureus
bacteraemia.
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conducted in adults with SAB, and reflect current best
practice.
Follow-up blood cultures have been recommended in
adults, as prolonged bacteraemia is a predictor of compli-
cated infection and poorer outcome in SAB.36 As a result,
prolonged intravenous antibiotic therapy is recom-
mended in patients with positive repeat blood cultures.
We found that children who had a positive repeat blood
culture were more likely to receive a longer course of
intravenous antibiotics if they were in the IDC group.
Echocardiography was performed in a higher propor-
tion of children in the IDC group compared with the
pre-IDC group. The rates of IE in children with SAB are
reported to be between 0% and 20%, which is similar to
rates reported in the adult population.1 3 6 8 12 40–42 An
American study by Valente et al40 diagnosed IE in 20%
of children with SAB (∼12% of whom had confirmed
IE). Children with underlying congenital heart disease
had a higher prevalence of confirmed or probable IE
compared with those who had structurally normal hearts
(53% vs 3%) and patients with definite IE had multiple
positive blood cultures. Mortality was higher in patients
with endocarditis compared with those without (40% vs
12%). Another study from South Africa reported an IE
rate of 11% in children with SAB.12 Risk factors for the
development of IE in children include congenital heart
disease, a central IVC and persistently positive blood cul-
tures after 24 h.40 41 In the UK, there are no published
guidelines on the use of echocardiography in children
with SAB. The Infectious Diseases Society of America
guidelines for meticillin-resistant S. aureus (MRSA) bac-
teraemia recommend performing echocardiography in
Table 1 Baseline characteristics of children with Staphylococcus aureus bacteraemia included in the study
Baseline variable
Pre-IDC group IDC group Combined
N=28 patients (%) N=35 patients (%) N=63 patients (%)
Male 20 (71.4) 20 (57.1) 40 (63.5)
Female 8 (28.6) 15 (42.9) 23 (36.5)
Median age in years (IQR) 4.3 (0.2–9.4) 3.4 (0.2–12.2) 3.4 (0.2–10.7)
Neonates 6 (20) 9 (25.0) 15 (23.8)
Prematurity 4 (66.7) 9 (100.0) 13 (86.7)
Median age in days (IQR) 11 (7–47) 26 (23–38) 25 (14–47)
Median birth weight in grams (IQR) 1117 (630–3535) 820 (755–1120) 830 (710–1330)
Congenital heart disease 5 (17.9) 8 (22.9) 13 (20.6)
Chronic pulmonary disease 3 (10.7) 5 (14.3) 8 (12.7)
Liver disease 0 1 (2.9) 1 (1.6)
Malignancy 7 (25.0) 9 (25.7) 16 (25.4)
Metastatic cancer 2 (7.1) 1 (2.9) 3 (4.8)
Neurological condition 4 (14.3) 13 (37.1) 17 (27.0)
Diabetes mellitus 0 1 (2.9) 1 (1.6)
Skin condition 3 (10.7) 1 (2.9) 4 (6.4)
Atopic dermatitis 3 (100.0) 3 (75.0)
Immunosuppression 6 (21.4) 8 (22.9) 14 (22.2)
Corticosteroid therapy 2 3 5
Antineoplastic 5 5 10
Neutropenia 2 0 2
N=30 episodes (%) N=36 episodes (%) N=66 episodes (%)
Mode of acquisition
Community-acquired 11 (36.7) 10 (27.8) 21 (31.8)
Healthcare-associated 9 (30.0) 7 (19.4) 16 (24.2)
Hospital-acquired 10 (33.3) 19 (52.8) 29 (43.9)
Duration of symptoms of bacteraemia (hours)
0–24 21 (70.0) 18 (50.0) 39 (59.1)
25–72 1 (3.3) 6 (16.7) 7 (10.6)
>72 7 (23.3) 10 (27.8) 17 (25.8)
Unknown 1 (3.3) 2 (5.6) 3 (4.6)
Organism
MSSA 28 (93.3) 33 (91.7) 61 (92.4)
MRSA 2 (6.7) 3 (8.3) 5 (7.6)
C reactive protein (nmol/L) 333 (114–890) 448 (181–1081) 390 (133 –1005)
White cell count (109/L) 8.8 (5.8–15.6) 10.1 (6.9–18.4) 9.6 (6.3–16.5)
Neutrophils (109/L) 5.4 (3.6–9) 6.3 (4.9–11.8) 5.7 (3.6–11.8)
Platelets (109/L) 277 (151–374) 213 (101–270) 224 (140–301)
IDC, infectious diseases consultation; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus
aureus.
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children with congenital heart disease, those with bacter-
aemia duration greater than 2 days or those with other
clinical findings suggestive of endocarditis.35 In our
study, the one child who developed tricuspid valve endo-
carditis was a very low birthweight premature neonate
with a patent ductus arteriosus, an IVC-related infection
and persistent bacteraemia. Our findings concur with
these guidelines, and support the use of a risk-based
strategy for the use of echocardiography in children
with SAB.
We found that a higher proportion of children had an
IVC-related infection and/or a removable focus of infec-
tion in the IDC group compared with the pre-IDC
group, although neither of these differences was statistic-
ally significant. It is possible that IVC was used more
during the IDC period compared with the pre-IDC
period. Although removable foci of infection were more
frequently identified and removed in the IDC group
compared with the pre-IDC group, the median time to
removal was slightly longer (3 vs 2 days). In some cases,
this was related to practical difficulties in removing the
focus, such as re-establishing vascular access in neonates.
Conversely, there were fewer patients with an unidenti-
fied focus of infection in the IDC group compared with
the pre-IDC group. These findings indicate that the
introduction of specialist IDC service improved the rate
of diagnosis of the focus of infection in children with
SAB, suggesting that the consult service was beneficial.
The frequency of MRSA bacteraemia was only 7.6% in
our study cohort. Possible explanations for this are that
MRSA bacteraemia is less common in children than in
adults, and that MRSA bacteraemia rates have signifi-
cantly declined in the UK since 2006. In contrast, in
other countries such as the USA, the incidence of MRSA
bloodstream infections has been higher than in the UK,
but has recently declined. In a large retrospective study
Table 2 Clinical features of Staphylococcus aureus bacteraemia in children included in the study
Focus of infection at
time of bacteraemia
Pre-IDC group
N=30 episodes (%)
IDC group
N=36 episodes (%)
Combined
N=66 episodes (%) p Value
Unknown focus 7 (23.3) 2 (5.6) 9 (13.6) NS
Intravascular catheter 8 (26.7) 22 (61.3) 30 (45.5) 0.013
Culture confirmed 5 (62.5) 11 (50.0) 16 (53.3) NS
Thrombophlebitis 0 2 (5.7) 2 (3.0) NS
Bone/joint infection 8 (26.7) 8 (22.2) 16 (24.2) NS
Culture confirmed 4 (50.0) 2 (25.0) 6 (37.5) NS
Lung 1 (3.3) 1 (2.8) 2 (3.0) NS
Culture confirmed 0 1 (100.0) 1 (50) NS
Skin and soft tissue 7 (23.3) 9 (25.0) 16 (24.2) NS
Culture confirmed 4 (57.1) 8 (88.9) 12 (75.0) NS
Deep tissue abscess 2 (6.7) 1 (2.8) 3 (4.6) NS
Culture confirmed 2 (100.0) 0 2 (66.7) NS
Other focus 2 (6.7) 4 (11.1) 6 (9.1) NS
Defervescence at 72 h
Yes 18 (60.0) 20 (55.6) 38 (57.6) NS
No 11 (36.7) 14 (38.9) 25 (37.9)
Unknown 1 (3.3) 2 (5.6) 3 (4.6)
IDC, infectious diseases consultation; NS, non-significant.
Table 3 Risk factors for Staphylococcus aureus bacteraemia in children included in the study
Risk factor for SAB
Pre-IDC group
N=30 episodes (%)
IDC group
N=36 episodes (%)
All children
N=66 (episodes) p Value
Age <1 year 11 (36.7) 14 (38.9) 25 (37.9) NS
Underlying medical condition 16 (53.3) 24 (66.7) 40 (60.6) NS
Duration in hospital in days (IQR)
Prior to bacteraemia*
11.5 (7.0–21.0) 19.0 (12.0–37.0) 16.0 (8.0–24.0) NS
Prosthetic material 14 (46.7) 26 (72.2) 40 (60.6) 0.04
Intravascular line 13 (43.3) 23 (63.9) 36 (54.6) NS
Endotracheal tube 0 4 4 NS
Other 1 6 8 NS
corticosteroid therapy 2 (6.7) 3 (8.3) 5 (7.6) NS
Surgery within previous 30 days 4 (13.3) 4 (11.1) 8 (12.1) NS
*Hospital-acquired infection only.
IDC, infectious disease consultation; NS, non-significant.
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of over 57 000 hospitalised children with S. aureus infec-
tions, 51% had MRSA and 61% had MRSA skin and soft
tissue infections. The incidence of skin and soft tissue
infections, pneumonia, osteomyelitis and bacteraemia
increased over time but overall mortality was low (1%).
Thus, the findings of our study may not be generalisable
to other settings where the epidemiology and outcomes
of MRSA bacteraemia are different.
Table 4 Comparison of the management and outcome of Staphylococcus aureus bacteraemia in children, preintroduction
and postintroduction of an infectious disease consult service
Quality indicator
Pre-IDC group
N=30 episodes (%)
IDC group
N=36 episodes (%) p Value
Median time to infectious diseases review in days (IQR) N=4
3.5 (0.5–21.5)
N=34
2.0 (1.0–4.0)
NS
Repeat blood culture performed 26 (86.7) 32 (88.9) NS
Time to repeat blood culture (h)
0–48 20 18 NS
48–96 8 13 NS
>96 1 1 NS
Repeat blood culture positive (h)
0–48 6 6 NS
48–96 3 4 NS
>96 0 0 NS
Echocardiogram performed
Yes 10 (33.3) 29 (80.6) 0.0001
No 20 (66.7) 7 (19.4)
β-Lactam therapy 27 (90.0) 34 (94.4) NS
MSSA 25 (92.6) 33 (97.1)
Removable focus of infection 7 (23.3) 22 (43.9) 0.003
Focus removed 6 (85.7) 21 (95.5) NS
Median time to removal in days (IQR) 2.0 (2.0–2.0) 3.0 (1.0–18.0) NS
Median time to appropriate antibiotics in days (IQR) 0.0 (0) 0.0 (0) NS
Median duration of intravenous antibiotics in days (IQR) 13.5 (7.0–21.0) 18.0 (15.0–29.0) 0.035
Median duration of intravenous and/or oral antibiotics in days (IQR) 20.5 (16.0–42) 19.0 (15.0–29.5) NS
Complicated infection
N=15 episodes
Days (IQR)
N=19 episodes
Days (IQR)
Median duration of intravenous antibiotics 14.0 (6.0–21.0) 22 (15.0–39.0) 0.02
Median duration of intravenous or oral antibiotics 19.0 (17.0–43.0) 27.0 (16.0–39.0) NS
Median duration of intravenous antibiotics if repeat blood
culture positive
13.0 (6.0–14.0) 19.0 (15.0–27.0) 0.007
Met standard recommendation of 28 days intravenous antibiotics (%) 2 (13.3) 8 (42.1) NS
Uncomplicated infection
N=15 episodes
Days (IQR)
N=17 episodes
Days (IQR)
Median duration of intravenous antibiotics 13.0 (7.0–22.0) 15.0 (14.0–21.0) NS
Median duration of intravenous or oral antibiotics (IQR) 22.0 (14.0–32.0) 18.0 (14.0–29.0) NS
Met standard recommendation of 14 days (%) 7 (46.7) 13 (68.4) NS
Outcomes
N=30 episodes
Days (IQR)
N=36 episodes
Days (IQR)
Median duration of hospital admission
Total 14.0 (6.0–42.0) 16.5 (7.5–58) NS
Complicated 20.0 (6.0–49.0) 25.0 (8.0–88.0) NS
Uncomplicated 7.0 (3.0–22.0) 11.0 (6.0–36.0) NS
SAB recorded in discharge summary 24 (80.0) 29 (82.9) NS
Secondary infection detected 1 3 NS
Outcomes 30-day post-SAB
Death 0 3 NS
Recurrence 0 0 NS
Outcomes 30–90 days post-SAB
Death 2 0 NS
Recurrence 2 1 NS
Mortality was analysed per patient (only the first episode was analysed).
IDC, infectious diseases consultation; NS, non-significant; SAB, Staphylococcus aureus bacteraemia.
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In terms of duration of antimicrobial therapy, we
found that patients in the IDC group received longer
courses of intravenous antibiotics in complicated infec-
tion, compared with patients in the pre-IDC group. This
concurs with findings from studies in adults with SAB,
and suggests that specialist infectious diseases review
may be beneficial in ensuring that clinical management
recommendations, such as the length of intravenous
antimicrobial therapy, are applied. There were, however,
no differences in mortality observed between the
pre-IDC and IDC groups. The most likely explanation
for this was the small study population, combined with a
low mortality rate, which meant that a large number of
patients would be required to demonstrate even a small
difference in mortality. Furthermore, the overall dur-
ation of antibiotic therapy was similar in the two groups.
It may be that total duration of antibiotic therapy is
more important than the route of administration, pro-
vided that adequate concentrations are achieved in the
bloodstream. Indeed, studies to examine this very ques-
tion, comparing short versus long courses of intravenous
antibiotics in SAB in adults, are ongoing. Finally,
although a removable focus of infection was identified
more frequently in the IDC group, the likelihood of
removal and the time to removal did not differ; this may
also explain the lack of difference in outcome between
the two groups.
We acknowledge several limitations to our study. The
study population was small and the differences in diag-
nosis and management that we observed in the two
groups did not translate into differences in outcome, for
reasons discussed above. The retrospective data collec-
tion during the pre-IDC period (2006–2009) carries a
risk of incomplete recording of data and potential bias.
There were, however, no differences in baseline
characteristics between the two groups in terms of age,
gender, underlying comorbidities or focus of infection.
The only exception was a higher frequency of
IVC-related infections in the IDC group, which may have
been under-recorded in the pre-IDC period and/or
diagnosed more frequently in the IDC period.
In conclusion, we found that introduction of IDC for
paediatric SAB resulted in improvements in manage-
ment and a more consistent approach to care across the
paediatric service. These findings concur with those of
previous studies of IDC in adults with SAB. Our findings
support the use of a targeted approach to echocardiog-
raphy in SAB in children, particularly for patients with
risk factors for complicated disease. Despite improve-
ments in the investigation and clinical management, we
did not find any differences in the development of sec-
ondary infections, recurrent bacteraemia or death
between the two groups. The most likely explanation for
this is the small study population and larger prospective
studies are required to validate our findings and to
determine the optimal strategies for investigation and
management of paediatric SAB.
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